Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

By Ulrich M. Zanger, S. Raimundo, M. Eichelbaum. Naunyn-Schmiedeberg's Archives of Pharmacology, 2003

841 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/0948e3576b3bedc129549615601d40344a766f14

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pharmacology

Citations in the corpus

Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. (2013, background): “The molecular studies that followed were reviewed previously (Meyer & Zanger, 1997; Zanger et al., 2004; Ingelman-Sundberg, 2005).”
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine (2016, background): “According to the probe substrate metabolic capabilities among the sampled individuals in a population, patients can be categorized into the following four phenotypic groups: poor, intermediate, extensive, and ultra-rapid metabolizers (PMs, IMs, EMs, and UMs), respectively [38].”
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. (2007, background): “…on the market (Evans & Relling, 1999; Eichelbaum et al., 2006), and its polymorphism significantly affects the metabolism of about 50% of these drugs (IngelmanSundberg, 2005; for recent reviews, see Kirchheiner et al., 2004a; Zanger et al., 2004; Ingelman-Sundberg, 2005; Bernard et al., 2006).”
Polymorphism of human cytochrome P450 enzymes and its clinical impact (2009, methodology): “Sparteine and debrisoquine had been widely used to determine the phenotype of CYP2D6-mediated metabolism (Llerena et al., 2009; Zanger et al., 2004).”
Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 (2004, background): “The metabolic activity of CYP2D6 exhibits high interindividual variability, mainly due to the polymorphism of the CYP2D6 gene (over 80 alleles and allele variants have been described, many of which result in loss of enzyme function) (Zanger et al., 2004) but also due to several drugs that potently i”